Stem definition | Drug id | CAS RN |
---|---|---|
steroids not used as glucocorticosteroids | 4976 | 5611-51-8 |
None
None
Date | Agency | Company | Orphan |
---|---|---|---|
July 29, 1969 | FDA | SANDOZ |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Human antichimeric antibody positive | 331.08 | 173.30 | 57 | 2306 | 1657 | 63485002 |
Body height below normal | 323.90 | 173.30 | 58 | 2305 | 2125 | 63484534 |
Polyarthritis | 260.59 | 173.30 | 63 | 2300 | 10083 | 63476576 |
Drug specific antibody | 255.25 | 173.30 | 48 | 2315 | 2307 | 63484352 |
Adrenal insufficiency | 220.48 | 173.30 | 62 | 2301 | 17853 | 63468806 |
Bone density decreased | 214.08 | 173.30 | 58 | 2305 | 14554 | 63472105 |
None
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Human antichimeric antibody positive | 345.86 | 165.36 | 57 | 2334 | 1584 | 79740413 |
Body height below normal | 339.97 | 165.36 | 58 | 2333 | 1995 | 79740002 |
Polyarthritis | 267.74 | 165.36 | 64 | 2327 | 12138 | 79729859 |
Drug specific antibody | 260.34 | 165.36 | 48 | 2343 | 2580 | 79739417 |
Bone density decreased | 231.72 | 165.36 | 58 | 2333 | 13289 | 79728708 |
Adrenal insufficiency | 201.00 | 165.36 | 61 | 2330 | 28426 | 79713571 |
Obesity | 176.24 | 165.36 | 58 | 2333 | 35067 | 79706930 |
Antibody test positive | 170.55 | 165.36 | 34 | 2357 | 2758 | 79739239 |
None
Source | Code | Description |
---|---|---|
FDA MoA | N0000175450 | Corticosteroid Hormone Receptor Agonists |
FDA EPC | N0000175576 | Corticosteroid |
MeSH PA | D000893 | Anti-Inflammatory Agents |
CHEBI has role | CHEBI:35472 | anti-inflammatory drugs |
CHEBI has role | CHEBI:50857 | anti-allergic drugs |
MeSH PA | D005938 | Glucocorticoids |
MeSH PA | D006728 | Hormones |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Lichen planus | indication | 4776004 | DOID:9201 |
Keloid scar | indication | 33659008 | |
Lichen simplex chronicus | indication | 53891004 | |
Necrobiosis lipoidica diabeticorum | indication | 56391002 | |
Alopecia areata | indication | 68225006 | DOID:986 |
Discoid lupus erythematosus | indication | 200938002 | |
Idiopathic thrombocytopenic purpura | contraindication | 32273002 | DOID:8924 |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 11.08 | acidic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Glucocorticoid receptor | Nuclear hormone receptor | AGONIST | DRUG LABEL | DRUG LABEL |
ID | Source |
---|---|
I7GT1U99Y9 | UNII |
D00985 | KEGG_DRUG |
4017601 | VUID |
N0000179269 | NUI |
4017599 | VANDF |
4017601 | VANDF |
C0077004 | UMLSCUI |
CHEBI:9670 | CHEBI |
CHEBI:9667 | CHEBI |
CHEMBL1200878 | ChEMBL_ID |
21826 | PUBCHEM_CID |
1907 | INN_ID |
C005900 | MESH_SUPPLEMENTAL_RECORD_UI |
DB00620 | DRUGBANK_ID |
10759 | RXNORM |
354456 | MMSL |
4582 | MMSL |
5613 | MMSL |
5616 | MMSL |
d00620 | MMSL |
002188 | NDDF |
002191 | NDDF |
116594009 | SNOMEDCT_US |
412524002 | SNOMEDCT_US |
6028009 | SNOMEDCT_US |
C0040864 | UMLSCUI |
755 | INN_ID |
31307 | PUBCHEM_CID |
D014221 | MESH_DESCRIPTOR_UI |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Hexatrione2% | HUMAN PRESCRIPTION DRUG LABEL | 1 | 59137-570 | INJECTION, SUSPENSION | 40 mg | INTRA-ARTICULAR | Unapproved drug for use in drug shortage | 3 sections |
Hexatrione2% | HUMAN PRESCRIPTION DRUG LABEL | 1 | 59137-570 | INJECTION, SUSPENSION | 40 mg | INTRA-ARTICULAR | Unapproved drug for use in drug shortage | 3 sections |